Kuo-Chu Lai
Kuo-Chu Lai |
||||
Appointments:Associate Professor |
Lab:Cell Cytotoxicity Laboratory |
|||
Education:Ph.D. |
School/Nation:National Yang Ming Chiao Tung University/Taiwan |
|||
Tel: #3035 |
E-mail: kuochu@mail.cgu.edu.tw |
|||
Research website: https://tcue504.weebly.com/ |
||||
研究室現有: 博士後研究員 人 |
博士班研究生 人 |
碩士班研究生 2 人 |
||
專任研究助理 1 人 |
大學部專題生 人 |
|
||
Research outline:(1-3 pages)
My major research interests are exploring the underlying mechanism of cancer cachexia and developing effective therapeutic agents against cancer growth and progression. Our studies will provide new insight into the cancer cachexia and potential strategies for cancer treatment.
Head and neck cancer (HNC) is the sixth most common cancer in the world. There are 600,000 new cases of HNC are diagnosed worldwide each year each year. Epidemiological studies over last 20 years reveal that the overall incidence of young patients under 45 who encounter HNC, especially oral squamous cell carcinoma (OSCC), is growing steadily. Therefore, understanding the molecular mechanism of HNC progression is the basis for developing therapeutic strategies. Our preliminary results have demonstrated that interferon induced protein with tetratricopeptide repeats 2 (IFIT2) depletion could enhance epithelial-mesenchymal transition (EMT), migration, invasion, angiogenesis, and metastasis, suggesting that IFIT2 may act as a metastasis suppressor. More currently, we found that mice bearing HNC cells expressing sh-IFIT2 exhibited cachexia syndrome. Cachexia syndrome is one of the most lethal effects in cancer patients. The frequency of cancer-related cachexia is considerably high (60-80%) in HNC. However, the detail mechanisms responsible for cancer cachexia are poorly understood. Therefore, we aim to investigate the role of IFIT2 in HNC cachexia..
II. Discovery and development of anticancer agents from natural products or novel synthetic chemicals In the past, we have made efforts to examine the anti-tumor effects of natural products, such as oroxylin A, Antrodia cinnamomea (AC) and novel synthetic quinazolinone derivatives. To mimic the chronic use of natural products, we established an in vitro long-term treatment model and demonstrated that oroxylin A inhibition of migration following long-term treatment may be due to its suppression of CCL2 in OSCC cells. Moreover, we explored the antitumor effect of novel Antrodia cinnamomea extract on colorectal cancer cells. We are currently focusing on the anti-tumor effects of novel DNA bifunctional alkylating agents and quinazoline derivations. In the future, more natural products or novel synthetic chemicals will be tested. |
||||
Publications:
|